Patents by Inventor Fengqi CAO

Fengqi CAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230112450
    Abstract: Provided herein are a combination of antitumor medicaments comprising a TRAIL-R2 agonistic antibody (e.g., CTB006) and Ponatinib or its hydrochloride. Also provided herein are a method of treating tumors that include administering therapeutically effective amounts of a TRAIL-R2 agonistic antibody and Ponatinib or its hydrochloride to a patient. The synergistic effect of these two medicaments helps to enhance the effect of tumor treatment.
    Type: Application
    Filed: March 5, 2021
    Publication date: April 13, 2023
    Applicant: Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd.
    Inventors: Xiaoyan ZHONG, Fengqi CAO, Zhe LI
  • Publication number: 20220251211
    Abstract: Provided is an isolated antibody or antigen-binding fragment thereof that binds specifically to human CD-L1 protein, a nucleic acid molecule encoding the same, therapeutic compositions thereof, and their use to treat a PD-L1 related disease, such as a tumor which is PD-L1 positive.
    Type: Application
    Filed: July 19, 2019
    Publication date: August 11, 2022
    Applicant: Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd.
    Inventors: Tong ZHOU, Fengqi CAO, Zhe LI, Xiuli JIN
  • Publication number: 20180333491
    Abstract: TRAIL receptor-binding agents have therapeutic effects on tumor inhibition in vitro and in vivo, alone or in combination with an anti-cancer biologic. In particular, methods for the treatment of cancer include administering a TRAIL receptor binding agent, alone or in combination with TRAIL and/or interferon ?-2b.
    Type: Application
    Filed: August 19, 2015
    Publication date: November 22, 2018
    Inventors: Enyun SHEN, Fengqi CAO, Zhe LI